Beyond XDR TB. Case Presentation. Past Medical History. Caitlin Reed 2014 National TB Conference Atlanta, Georgia June 12, 2014
|
|
|
- Claude Terry
- 7 years ago
- Views:
Transcription
1 Beyond XDR TB Caitlin Reed MD, MPH Medical Director, Inpatient TB Unit Assistant Professor, Division of Infectious Diseases Olive View UCLA Medical Center Los Angeles County Department of Health Services Case Presentation 38 yo M, Armenian ethnicity, lived in Russia and US Infliximab started July 2013 for ankylosing spondylitis +TST, LTBI treatment with INH Rif Cough, wt loss, fevers x several months prior to hospital admission December 2013 Past Medical History Ankylosing spondylitis, dx 2005 Polysubstance abuse including opiates chronic PNA in Russia, self treated with oral Abx and injections Page 1
2 Diagnosis of Tuberculosis Tm in ED, cachetic LUL infiltrate on CXR Sputum 4+ AFB smear and culture positive for Mycobacterium tuberculosis CXR 12/3/13 Emergency Department Initial Susceptibility Report Drug Critical Concentration (mcg/ml) Interpretation Isoniazid 0.4 Resistant Rifampin 1.0 Resistant Ethambutol 5.0 Resistant Pyrazinamide 100 Susceptible Page 2
3 Molecular Detection of Drug Resistance at CDC Locus Result Interpretation rpob Likely RIF R inha katg embb pnca gyra rrs eis (promoter) tlya GAC>GC; Asp516Gly; CTG>CCG; Leu83Pro No mutation AGC>ACC Ser315Thr ATG>GTG; Met308Val TAC>GAC; Tyr103Asp TCG>CCG; Ser91Pro No mutation G 10 A No mutation INH R EMB R Unknown effect on PZA resistance Likely Oflox R Likely Kanamycin R; Cannot r/o resistance to AMK and CAP Initial MDR Regimen 12/26/13 Moxifloxacin Capreomycin Linezolid PZA PAS Ethionamide Cycloserine Meropenem Amox/Clavulanate CXR OVMC 1/31/14 Page 3
4 CT Chest 2/27/14 CDC DSTs Drug % R Interp. Drug % R Interp. INH R Kanamycin R INH R Ethionamide R INH R Capreomycin R RIF R PAS R SM R Ofloxacin R SM R Amikacin R RFB R CIPRO R Summary of Drug Susceptibility Reports Page 4
5 XDR Regimen selection Linezolid Cycloserine Bedaquiline Clofazimine PAS Amikacin Moxi Doripenem Amox/Clav Known or likely susceptible Resistant, but uncertain what this means Discrepant results. May have some activity if level by TDM at least 4x > MIC. Push doses to maximum tolerated. Lowest MIC of available carbapenems. Clavulanate potentiates. Time to Culture Positivity Weeks to positive culture MDR regimen BDQ + Clofaz added Weeks from treatment initiation Sputum smear grade Response to treatment MDR regimen BDQ + Clofaz added Weeks from treatment initiation Page 5
6 Response to treatment Weight (kg) BDQ + Clofaz added Weeks from treatment initiation Follow up CT CT Chest 5/7/14 Bedaquiline Cost: $30,000 (or $23,000 for public health depts in outpatient setting only) Cost front loaded May take weeks to obtain Only one pharmacy in US (MMS in Tennessee) Registry in development QT interval monitoring recommended Page 6
7 Toxicities Worsening peripheral neuropathy Moxifloxacin d/c ed Linezolid held and resumed at reduced dose Rising Cr from 0.4 to 0.9 Baseline hearing loss, slightly worse Concern for how long regimen can be maintained Hospital Course Converted to culture negative x 5 Finally out of isolation, preop workup Transferred for L pneumonectomy 6/3/14 Lessons Learned There will be discrepancies in DSTs Use clinical judgment and expert input to interpret MICs and Therapeutic Drug Monitoring (TDM) helpful in building XDR background regimen Adverse effects of regimen significant Surgery has role Costs of care high Inpatient specialty TB care helpful Page 7
8 Additional slides Therapeutic Drug Monitoring Drug 2 hr 6 hr Target range PAS mcg/ml 4gm po bid Ethionamide 250 mg po qam, 500 qpm mcg/ml CS 250 mg po bid PZA 1500 mg po qday Linezolid 600 mg po qday Moxi 600 mg po qday mcg/ml mcg/ml mcg/ml mcg/ml Pyrazinamide Date Lab Method Result Interpretation collected 12/4/13 CDC Molecular detected U (pnca) 12/4/13 ARUP MGIT 100 ug/ml S 12/4/13 NJH MGIT MIC > 400 ug/ml R 12/4/13 CA MDL MGIT 100 ug/ml R 2/2/14 CDC MGIT 100 ug/ml R Page 8
9 Moxifloxacin Date Lab Method Result Interpretation collected 12/6/13 CA MDL PSQ detected U (gyra) 12/4/13 CA MDL MGIT 0.25 ug/ml R MIC = 2 ug/ml 2/2/14 FL PHL MIC = 8 ug/ml U 2/2/14 JHU MIC = 4 ug/ml R 2/2/14 CA MDL MGIT 0.25 ug/ml MIC = 2 ug/ml R Ethionamide Date collected Lab Method Details Interpretation 12/4/13 CDC AP 10 ug/ml R 12/4/13 CA MDL MGIT 5 ug/ml S 2/2/14 JHU MIC = 10 ug/ml R 2/2/14 NJH 8 ug/ml R 2/2/14 FL PHL MIC = 2.5 ug/ml R 2/2/14 CA MDL MGIT 5 ug/ml S 2/2/14 CDC AP 10 ug/ml R PAS Date collected Lab Method Result Interpretation 12/4/13 CDC AP 2 ug/ml R 12/4/13 NJH AP 8 ug/ml S 2/2/14 JHU MIC = 8 ug/ml S 2/2/14 CDC AP 2 ug/ml S 2/2/14 FL PHL MIC = 2 ug/ml U 2/2/14 NJH AP 8 ug/ml S Page 9
10 Clofazimine Date collected Lab Method Result Interpretation 12/4/13 NJH AP 0.5 ug/ml R 2/2/14 JHU MIC = 0.5 ug/ml U 2/2/14 NJH AP 0.5 ug/ml R Cycloserine Date collected Lab Method Result Interpretation 12/4/13 NJH AP 60 ug/ml S 2/2/14 JHU MIC = 64 ug/ml U 2/2/14 NJH 60 ug/ml S 2/2/14 FL PHL MIC = 32 ug/ml U Amikacin Date Lab Method Result Interpretation collected 12/4/13 CDC MDDR detected U (eis) 12/6/13 CA MDL PSQ No mutation detected S (rrs) 12/4/13 CDC AP 4.0 ug/ml R 12/4/13 CA MDL MGIT 1.5 ug/ml R 2/2/14 JHU MIC >16 ug/ml R 2/2/14 FL PHL MIC = 2 ug/ml S 2/2/14 CA MDL MGIT MIC = 3 ug/ml R 2/2/14 CDC AP 4.0 ug/ml S Page 10
Recent Advances in The Treatment of Mycobacterium Tuberculosis
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA mohdarif035@salam.uitm.edu.my
Tuberculosis in Children and Adolescents
Tuberculosis in Children and Adolescents Ritu Banerjee, MD, Ph.D TB Clinical Intensive April 8, 2015 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Describe the epidemiology of pediatric
Management of Tuberculosis: Indian Guidelines
Chapter 105 Management of Tuberculosis: Indian Guidelines Kuldeep Singh Sachdeva INTRODUCTION Tuberculosis (TB) is an infectious disease caused predominantly by Mycobacterium tuberculosis and among the
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for HIV, STD, and TB Prevention Division of Tuberculosis Elimination Public
MODULE THREE TB Treatment. Treatment Action Group TB/HIV Advocacy Toolkit
MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015
Introduction to TB Nurse Case Management Online February 4, 11, 18 and 25, 2015 Completion of Treatment: Case Studies or A Little Bit of Everything Presented by Cherie Fulk February 25, 2015 Cherie Fulk
Self-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Treatment of Latent Tuberculosis Infection and Tube rc ulos is Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National
Chapter 6 Treatment of Tuberculosis Disease
Chapter 6 Treatment of Tuberculosis Disease Table of Contents Chapter Objectives.... 139 Introduction.... 141 Treatment and Monitoring Plan.... 143 Adherence Strategies... 143 TB Disease Treatment Regimens....
Three Generations of MDR TB Expert Network Conference 11/12/2013
Three Generations of MDR TB Expert Network Conference 11/12/2013 VS 1 st AGH admission for this 63 yo Russian male who was admitted from Osceola County on 8/23/05 for treatment of MDR-TB Patient with history
Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015
TB burden and treatment guidelines Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, 23-26 November 2015 Outline Latest epidemiological data Global programme
MANAGEMENT OF TUBERCULOSIS
MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION
The endtb Project: Expanding New Drugs for TB PARTNERS IN HEALTH (PIH) MÉDECINS SANS FRONTIÈRES (MSF) INTERACTIVE RESEARCH & DEVELOPMENT (IRD)
The endtb Project: Expanding New Drugs for TB PARTNERS IN HEALTH (PIH) MÉDECINS SANS FRONTIÈRES (MSF) INTERACTIVE RESEARCH & DEVELOPMENT (IRD) April 29 th, 2015 Geneva, Switzerland Summary of endtb endtb
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
Tuberculousmeningitis: what is the best treatment regimen?
Tuberculousmeningitis: what is the best treatment regimen? H S Schaaf Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University
Treatment of DR-TB in children and preventive therapy for children exposed to DR-TB H Simon Schaaf
Treatment of DR-TB in children and preventive therapy for children exposed to DR-TB H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg
Treatment. Introduction... 32. Individualized Regimens.. 33. Selection and Dosing of Drugs... 41. Administration of the Regimen...
Treatment 3 Introduction............ 32 Individualized Regimens.. 33 Monoresistance......... 33 Polyresistance.......... 34 Multidrug Resistance..... 35 Extensive Drug Resistance 39 Selection and Dosing
Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant Tuberculosis Patients Treated in Virginia, 2009 2014
ORIGINAL ARTICLE http://dx.doi.org/10.4046/trd.2015.78.2.78 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2015;78:78-84 Outcomes and Use of Therapeutic Drug Monitoring in Multidrug-Resistant
Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
Chapter Four: Treatment of Tuberculosis Disease
Chapter Four: Treatment of Tuberculosis Disease The standard of tuberculosis (TB) treatment in Los Angeles County (LAC) is to initiate an appropriate chemotherapeutic regimen along with Directly Observed
Elisabeth Patton, DVM, PhD, Diplomate ACVIM
Brian Odegaard, RN BSN Public Health Madison & Dane County Diana Haley, RN BSN Sauk County Health Department Elisabeth Patton, DVM, PhD, Diplomate ACVIM Veterinary Program Manager Wisconsin Department
Chapter 1 Overview of Tuberculosis Epidemiology in the United States
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
PEDIATRIC TUBERCULOSIS. Hot topics / Unresolved issues in Clinical Practice
PEDIATRIC TUBERCULOSIS Hot topics / Unresolved issues in Clinical Practice Ann M. Loeffler, M.D. Legacy Emanuel Children s Hospital Portland, OR Faculty Consultant Francis J. Curry National TB Center February
Guideline. Treatment of tuberculosis in pregnant women and newborn infants. Version 3.0
Guideline Treatment of tuberculosis in pregnant women and newborn infants Version 3.0 Key critical points The decision to treat tuberculosis (TB) in pregnancy must consider the potential risks to mother
TB preventive therapy in children. Introduction
TB preventive therapy in children H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg Children s Hospital Introduction Children are
Management of Adverse Drug Reactions in Tuberculosis. Anju Budhwani, MD
Management of Adverse Drug Reactions in Tuberculosis Anju Budhwani, MD Introduction Management of patients with tuberculosis (TB) can be a difficult task in any patient Drug reactions commonly occur in
TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
Challenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department
Challenges in Pediatric Tuberculosis Mimi Emig, MD Spectrum Health Kent County Health Department Pediatric Tuberculosis: A Missed Public Health Opportunity Mimi Emig, MD Spectrum Health Kent County Health
Guideline. Treatment of tuberculosis in renal disease. Version 3.0
Guideline Treatment of tuberculosis in renal disease Version 3.0 Key critical points Renal failure is recognised as a risk factor for developing tuberculosis. Renal failure is recognised as a risk factor
Tuberculosis Trials Consortium (TBTC) Update on New Drug Work for DS TB 2012
Tuberculosis Trials Consortium (TBTC) Update on New Drug Work for DS TB 2012 Stop TB Work Group on New Drugs Annual Meeting, Kuala Lumpur, 2012 Clinical Development of TB Drugs Payam Nahid, MD, MPH Tuberculosis
Treatment of Tuberculosis
Morbidity and Mortality Weekly Report Recommendations and Reports June 20, 2003 / Vol. 52 / No. RR-11 Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America
April King-Todd 2014 National TB Conference Atlanta, Georgia June 10, 2014
An Outbreak of TB Among the Homeless: The Aftermath in a High Incidence County April King-Todd, RN, MPH Los Angeles County Department of Public Health Tuberculosis Control Program National TB Nurses Coalition
Pediatric Latent TB Diagnosis and Treatment
Date Updated: April 2015 Guidelines Reviewed: 1. CDC Latent TB Guidelines 2. Harborview Pediatric Clinic Latent TB Management, 2010 3. Pediatric Associates Latent TB Guidelines, 2013 4. Seattle Children
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California
Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California 1 of 7 Table of Contents Preface 2 TB Symptoms and TB History 2 Initial Screening 2 Follow-Up Screening
Chapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI.... 112 LTBI Treatment Regimens.... 118 LTBI
TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG
TUBERCULOSIS (TB) SCREENING GUIDELINES FOR RESIDENTIAL FACILITIES AND DRUG Tx CENTERS Tuberculosis Control Program Health and Human Services Agency San Diego County INTRODUCTION Reducing TB disease requires
Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide
Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide Photo: Justin Ide First Edition: November, 2012 This handbook is made possible by the support of the American people through the
Performance Evaluation and Clinical Application of MTB NAAT in Orange County, CA. Minoo Ghajar Orange County Public Health Laboratory
Performance Evaluation and Clinical Application of MTB NAAT in Orange County, CA Minoo Ghajar Orange County Public Health Laboratory TB Case Count and Rate: Orange County, CA and the United States, 2012
Guideline. Treatment of tuberculosis in adults and children Version 2.1 July 2015
Guideline Treatment of tuberculosis in adults and children Version 2.1 July 2015 Contents What this guideline covers:... 1 What this guideline does not cover:... 1 Standard regimens for pulmonary tuberculosis...
Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis. Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva
Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva 1 Outline of Presentation Statement of the problem Common
Why Do Some Antibiotics Fail?
Why Do Some Antibiotics Fail? Patty W. Wright, M.D. April 2010 Objective To outline common reasons why antibiotic therapy is not successful and how this can be avoided. And to teach you a little bit about
Emerging Infectious Disease (4): Drug-Resistant Tuberculosis
S67 Drug-Resistant Tuberculosis Emerging Infectious Disease (4): Drug-Resistant Tuberculosis Chi-Fang You, MD; Han-Ping Ma, MD; Tzong-Luen Wang, MD, PhD; Aming Chor-Min Lin, MD Abstract Before the discovery
New York City Department of Health Protocols for Latent TB Infection Treatment
New York City Department of Health Protocols for Latent TB Infection Treatment CONTENT A. Medical evaluation for latent TB infection (LTBI) treatment 1. Medical history and physical examination 2. Chest
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)
Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults) H S Schaaf Department of Paediatrics and Child Health, and Desmond Tutu TB Centre Stellenbosch University, and Tygerberg
Tuberculosis and You A Guide to Tuberculosis Treatment and Services
Tuberculosis and You A Guide to Tuberculosis Treatment and Services Tuberculosis (TB) is a serious disease that can damage the lungs or other parts of the body like the brain, kidneys or spine. There are
New Jersey Department of Health and Senior Services. Standards of Care for Tuberculosis Disease and Latent TB Infection
New Jersey Department of Health and Senior Services Standards of Care for Tuberculosis Disease and Latent TB Infection Tuberculosis Medical Advisory Board March 2007 Table of Contents Standard # 1: Diagnosis
Main objectives in TB Rx
Treatment of Tuberculosis in Children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Main objectives in TB Rx To rapidly kill most bacilli in order
How To Treat Tuberculitis
Treatment of Tuberculosis Disease CONTENTS Introduction... 6.2 Purpose... 6.2 Policy... 6.2 Forms... 6.3 Reporting Requirements... 6.3 Basic Treatment Principles... 6.4 Treatment Regimens and Dosages...
TB and HIV Co-infection Update: Global Becomes Local
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb TB and HIV Co-infection Update: Global Becomes Local Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB
Treatment of Tuberculosis Disease
Treatment of Tuberculosis Disease CONTENTS Introduction... 6.2 Purpose... 6.2 Policy... 6.2 Forms... 6.3 Basic Treatment Principles... 6.4 Treatment Regimens and Dosages... 6.6 Regimens... 6.6 Dosages...
Questions and Answers About Tuberculosis
Questions and Answers About Tuberculosis 2014 Questions and Answers About Tuberculosis 2014 Questions and Answers About Tuberculosis ( TB) was written to provide information on the diagnosis and treatment
Monitoring Patients. Initial Evaluation... 128. Documentation... 129. General Monitoring... 129. Specific Monitoring... 130. Monitoring Tools...
6 Monitoring Patients Initial Evaluation........ 128 Documentation......... 129 General Monitoring..... 129 Specific Monitoring..... 130 Drug Administration..... 130 Absorption, Interactions. 130 Weight,
You. guide to tuberculosis treatment and services
Adapted from TB and You: A Guide to Tuberculosis Treatment and Services with permission from Division of Public Health TB Control Program State of North Carolina Department of Health and Human Services
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges John B. Kaneene, DVM, MPH, PhD University Distinguished Professor of Epidemiology Director, Center for Comparative Epidemiology
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol)
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,
Clinical Scenarios In Childhood TB. Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C
Clinical Scenarios In Childhood TB Josefina Cadorna Carlos M.D., FPPS, FPIDSP, FSMID Associate Professor of Pediatrics U E R M M M C Objectives: To present different commonly encountered clinical scenarios
Date: Referring Facility: Phone#: Anticipated Patient Needs (Please check appropriate boxes and include details within referral paperwork)
Barbara McInnis House Initial Referral Form Please fill form out completely. Include additional forms if prompted. Fax to Admissions Department. Follow up with a phone call. Patient Name: DOB: Gender:
Case Management Treatment Plan for Active TB Disease
Case Management Treatment Plan for Active TB Disease The purpose of this form is to provide a checklist to organize the gathering of information in a TB case to ensure the best medical and public health
Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences
Coll et al. Genome Medicine (2015) 7:51 DOI 10.1186/s13073-015-0164-0 METHOD Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences Open Access Francesc Coll 1, Ruth McNerney
LEARNING OUTCOMES. Identify children at risk of developing TB disease. Correctly manage and refer children suspected of TB. Manage child contacts
TB in Children 1a TB IN CHILDREN 2 LEARNING OUTCOMES Identify children at risk of developing TB disease Correctly manage and refer children suspected of TB Manage child contacts 3 TB Infection and Disease
Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005 2010
Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005 2010 Sarah E. Smith, Julia Ershova, Natalia Vlasova, Elena Nikishova,
San Francisco Treatment Guidelines for Latent Tuberculosis Infection
City and County of San Francisco Department of Public Health Tuberculosis Control Unit Julie Higashi, MD, PhD Director Population Health Division Edwin M. Lee Mayor Disease Prevention and Control Branch
TB Drugs: Common Side Effects and Interactions. First-line Drugs 11/21/2012. Adverse Events of First-line TB Drugs
TB Drugs: Common Side Effects and Interactions L. Beth Gadkowski MD MPH MS Assistant Professor Division of Infectious Diseases Eastern Virginia Medical School First-line Drugs Isoniazid (INH) Rifampin
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background
Tuberculosis case management at the Auckland and Northland region DHBs: the diagnostic, clinical and public health processes in adults
Tuberculosis case management at the Auckland and Northland region DHBs: the diagnostic, clinical and public health processes in adults Auckland version Auckland/Northland Regional TB Liaison Group (TBLG)
CDHS/CTCA JOINT GUIDELINES Guidelines for the Treatment of Active Tuberculosis Disease. Table of Contents
Treatment of Tuberculosis Disease CDHS/CTCA JOINT GUIDELINES Table of Contents I. Basic Principles 1 A. Organization and Treatment 1 B. Treatment 1 C. Clinical Management Issues 2 II. Diagnosis 2 III.
2011 NTP Paediatric guidelines update- final draft
Childhood TB Investigation and management of children suspected to have tuberculosis (TB) or who are close contacts of a TB case (sputum smear positive or negative) Key facts Children who are close contacts
MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS POLICY GUIDELINES
MANAGEMENT OF DRUG-RESISTANT TUBERCULOSIS POLICY GUIDELINES 2010 FOREWORD The following policy guidelines are intended for use by health care professionals involved in the complex and difficult task of
1 : 9. Rajendra Prasad, Etawah
MANAGEMENT OF Drug resistant and multidrug resistant tuberculosis 1 : 9 Rajendra Prasad, Etawah Introduction Drug resistant tuberculosis (DR-TB) has been reported since the early days of introduction of
12 Points of Tuberculosis (TB) Patient Education
12 Points of Tuberculosis (TB) Patient Education Transmission of TB TB is a disease caused by the TB germ. The disease is mainly in the lungs (pulmonary TB), but the germ can travel to other parts of the
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015
Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015 2 Objectives Participants will be able to : Understand the Pathogenesis of Tuberculosis (TB) Identify the Goals of Public Health for TB Identify Hierarchy
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement
INT J TUBERC LUNG DIS 20(1):24 42 Q 2016 The Union http://dx.doi.org/10.5588/ijtld.15.0221 E-published ahead of print 17 November 2015 REVIEW ARTICLE Clinical implications of molecular drug resistance
Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, 2014. Frequently Asked Questions
Frequently Asked Questions A child has history of BCG vaccination, should they have TST or IGRA? According to the American Academy of Pediatrics Red Book (2012), Interferon Gamma Release Assay (IGRA) is
American Thoracic Society Documents
American Thoracic Society Documents American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis This Official Joint Statement
FUNDAMENTALS OF TB CASE MANAGEMENT
CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE FUNDAMENTALS OF TB CASE MANAGEMENT OBJECTIVES Upon completion of this session, participants will be able to: 1. Describe several components of the tuberculosis
Management of a child failing first line TB treatment.
Management of a child failing first line TB treatment. Robert Gie Desmond Tutu Tuberculosis Centre Department of Paediatric and Child Health Stellenbosch University South Africa. Tygerberg Hospital Complex
Treatment of Tuberculosis
Treatment of Tuberculosis 1a Taking TB Treatment 2 Learning outcomes Describe the use of TB case definitions & the management of TB patients Successfully treat TB using the appropriate regimen for the
Treatment of Patients with Drug Addiction and Tuberculosis: New Strategies for the Future Directions
Treatment of Patients with Drug Addiction and Tuberculosis: New Strategies for the Future Directions Iván D. Montoya, M.D., M.P.H. Deputy Director, Division of Pharmacotherapies and Medical Consequences
New anti-tuberculosis drugs and regimens: 2015 update
REVIEW TUBERCULOSIS New anti-tuberculosis drugs and regimens: 2015 update Lia D Ambrosio 1,6, Rosella Centis 1,6, Giovanni Sotgiu 2, Emanuele Pontali 3, Antonio Spanevello 4,5 and Giovanni Battista Migliori
Use of Nucleic Acid Amplification Tests in TB patients in California 2010-2012
Use of Nucleic Acid Amplification Tests in TB patients in California 2010-2012 Lisa Pascopella, PhD, MPH Pennan Barry, MD, MPH Tuberculosis Control Branch, Division of Communicable Disease Control, Center
DIRECTLY OBSERVED TREATMENT SHORT-COURSE (DOTS)
DIRECTLY OBSERVED TREATMENT SHORT-COURSE (DOTS) Protocol for Tuberculosis Demonstration Projects in Russia U.S. Centers for Disease Control and Prevention and U.S. Agency for International Development
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Assistant Prof., Deptt. of Community Medicine GMCH Chandigarh Problem Statement of TB in India India accounts for nearly 1/4 th of global
Tuberculosis Exposure Control Plan for Low Risk Dental Offices
Tuberculosis Exposure Control Plan for Low Risk Dental Offices A. BACKGROUND According to the CDC, approximately one-third of the world s population, almost two billion people, are infected with tuberculosis.
The Global Epidemic 3/25/14. Roadmap to the Future: TB Control & Elimination. TB Exposed: Pharmacologic Management of TB April 11, 2014
Diana Fortune RN BSN TB Program Manager New Mexico Department of Health TB Exposed: Pharmacologic Management of TB April 11, 2014 The Global Epidemic http://exposed.aeras.org/#_video2 Roadmap to the Future:
Development of New TB Drugs. Martino Laurenzi, MD, MPH 16 th Symposium Tuberculose de Muenchenwiler 22 mars 2007
Development of New TB Drugs Martino Laurenzi, MD, MPH 16 th Symposium Tuberculose de Muenchenwiler 22 mars 27 Outline of this Presentation TB treatment: past & present Role of the TB Alliance New TB drug
Pediatric Tuberculosis
Pediatric Tuberculosis Ana M. Alvarez, M.D. Division of Pediatric Infectious Diseases and Immunology University of Florida College of Medicine/Jacksonville Children are not small adults! Objectives At
Philadelphia TB Newsletter
Philadelphia Department of Public Health Philadelphia TB Newsletter Volume 6, 6, Issue Issue 1 1 WORLD TB DAY EDITION Spring 2012 500 S. Broad Street, 2nd Floor Philadelphia, PA 19146 Michael Nutter Mayor
TB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 TB in the HIV Patient Lisa Armitige, MD, PhD November 13, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
Treatment of Tuberculosis during Pregnancy
Treatment of Tuberculosis during Pregnancy SA HIV Clinician s Society Conference 25 September 2014 Rebecca Berhanu 1 Health Economics and Epidemiology Research Office, Faculty of Health Sciences, University
CIRCULATED FOR COMMENTS - Feb04 DRAFT. BHIVA treatment guidelines for TB/HIV infection
BHIVA treatment guidelines for TB/HIV infection February 2004 (DRAFT) Dr Anton Pozniak Contents 1.0 Introduction 2.0 Aims of TB treatment 3.0 Treatment Regimens 4.0 Drug/drug interactions 5.0 Overlapping
Core Curriculum on Tuberculosis: What the Clinician Should Know Sixth Edition 2013
Core Curriculum on Tuberculosis: What the Clinician Should Know Sixth Edition 2013 CS234269 To View or Order the Core Curriculum on Tuberculosis To view or download the Core Curriculum, please visit: www.cdc.gov/tb.
Pregnancy and Tuberculosis. Information for clinicians
Pregnancy and Tuberculosis Information for clinicians When to suspect Tuberculosis (TB)? Who is at risk of TB during pregnancy? Recent research suggests that new mothers are at an increased risk of TB
Abstract. 1. Basic underlying view
_ Abstract 1. Basic underlying view Mycobacterium tuberculosis Table 1 2. LTBI treatment subjects 1. Basic view 2. TB development risk factors and infection diagnosis i. HIV/AIDS ii. Hemodialysis for
Ginny Dowell, RN, BSN October 21, 2015. Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS
Principles of Nurse Case Management Ginny Dowell, RN, BSN October 21, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE EXPERTISE INNOVATION
Targeted Testing for Tuberculosis Infection
Targeted Testing for Tuberculosis Infection CONTENTS Introduction... 3.2 Purpose... 3.2 Policy... 3.2 When to Conduct Targeted Testing... 3.3 Approaches to increasing targeted testing and treatment for
Targeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children
C D H S / C T C A J O I N T G U I D E L I N E S Targeted Testing and Treatment of Latent Tuberculosis Infection in Adults and Children Targeted Skin Testing and Treatment of Latent Tuberculosis Infection
Laboratory Techniques for the Diagnosis of TB what s available? Dr. Annette Jepson
Laboratory Techniques for the Diagnosis of TB what s available? Dr. Annette Jepson Outline of Topics to be Covered Laboratory processing of sputum samples Culture techniques Molecular diagnostics New developments
Ministry of Public Health and Sanitation GUIDELINES FOR THE MANAGEMENT DRUG RESISTANT TUBERCULOSIS IN KENYA
Ministry of Public Health and Sanitation GUIDELINES FOR THE MANAGEMENT OF DRUG RESISTANT TUBERCULOSIS IN KENYA DIVISION OF LEPROSY, TUBERCULOSIS AND LUNG DISEASE March 2010 Table of Contents Table of Contents...
Patient Education CONTENTS. Introduction... 12.2
CONTENTS Introduction... 12.2 Purpose... 12.2 General Guidelines... 12.3 Language and Comprehension Barriers... 12.4 Education Topics... 12.5 Medical Diagnosis... 12.5 Contact Investigation... 12.6 Isolation...
Maximizing Rifamycins
Maximizing Rifamycins Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University of Florida Page
Tuberculosis Surveillance and Screening for Long Term Care Facilities in Colorado
Tuberculosis Surveillance and Screening for Long Term Care Facilities in Colorado Developed by the Colorado Medical Directors Association and The Colorado Department of Public Health and Environment Introduction: